Table 2. Summary of all adverse events reported during the trial.

	Treatment (n, %)	Placebo (n, %)	P
Treatment emergent adverse events
Total participants with ≥1	16 (21.1)	16 (20.5)	0.93
Related, likely related, or possibly related
Administration site conditions
Site pain	4 (5.3)	2 (2.6)	0.5
Site pruritus	1 (1.3)	0
Site urticaria	1 (1.3)	0
Contact dermatitis	0	2 (2.6)
Unrelated
Hypothyroidism	0	1 (1.3)	1.0
Lacrimation increase	1 (1.3)	0	1.0
Gastrointestinal
Abdominal pain	0	1 (1.3)	1.0
Diarrhea	0	1 (1.3)	1.0
Vomiting	1 (1.3)	0	1.0
Seasonal allergies	0	1 (1.3)	1.0
Infections
Appendicitis (*severe AE)	1 (1.3)	0	1.0
Blister infection	0	1 (1.3)	1.0
Folliculitis	1 (1.3)	0	1.0
Gastroenteritis, viral	0	1 (1.3)	1.0
Molluscum contagiosum	1 (1.3)	0	1.0
Nasopharyngitis	1 (1.3)	0	1.0
Sinusitis	1 (1.3)	0	1.0
Tinea versicolor	0	1 (1.3)	1.0
Upper respiratory tract infection	1 (1.3)	1 (1.3)	1.0
Injury	4 (5.3)	4 (5.1)	1.0
Musculoskeletal
Arthralgia	1 (1.3)	1 (1.3)	1.0
Back pain	2 (2.6)	0	0.3
Bone lesion	1 (1.3)	0	1.0
Groin pain	0	1 (1.3)	1.0
Osteochondrosis	0	1 (1.3)	1.0
Headache	0	1 (1.3)	1.0
Sciatica	0	1 (1.3)	1.0
Anxiety/depression	0	1 (1.3)	1.0
Asthma	0	1 (1.3)	1.0
Rhinorrhea	1 (1.3)	0	1.0
Ingrown nail	0	1 (1.3)	1.0